Akebia Therapeutics
AKBA
153 hedge funds and large institutions have $412M invested in Akebia Therapeutics in 2018 Q1 according to their latest regulatory filings, with 43 funds opening new positions, 49 increasing their positions, 37 reducing their positions, and 20 closing their positions.
1,347% more call options, than puts
Call options by funds: $3.24M | Put options by funds: $224K
115% more first-time investments, than exits
New positions opened: 43 | Existing positions closed: 20
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
32% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 37
16% more funds holding
Funds holding: 132 → 153 (+21)
6.08% more ownership
Funds ownership: 71.29% → 77.36% (+6.1%)
12% less capital invested
Capital invested by funds: $470M → $412M (-$58.5M)
Top Buyers
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$20.3M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
+$19.9M |
| 3 |
LCM
Laurion Capital Management
New York
|
+$13.5M |
| 4 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
+$12.2M |
| 5 |
Renaissance Technologies
New York
|
+$9.76M |
Top Sellers
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$12.3M |
| 2 |
Millennium Management
New York
|
-$5.13M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$4.54M |
| 4 |
Norges Bank
Oslo,
Norway
|
-$3.49M |
| 5 |
EI
EAM Investors
Solana Beach,
California
|
-$2.68M |
AKBA Hedge Fund Activity: Q1 2018 in Review
153 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Akebia Therapeutics (AKBA) for Q1 2018, worth a combined $412M — down 12% from $470M a quarter earlier.
Buyers outnumbered sellers: 43 funds opened new AKBA positions and 20 closed out — a net gain of 23 holders — while 49 added to existing stakes and 37 trimmed.
The largest buyer was Nantahala Capital Management, adding an estimated $20.3M. The largest seller was Farallon Capital Management, exiting entirely with an estimated $12.3M sold.
- 153 institutional investors held Akebia Therapeutics (AKBA) as of Q1 2018, up from 132 in Q4 2017.
- Funds reported $412M of Akebia Therapeutics stock for Q1 2018, down 12% quarter-over-quarter.
- 43 funds opened new Akebia Therapeutics positions in Q1 2018 and 20 closed out, a net change of +23 holders.
- The largest Akebia Therapeutics buyer in Q1 2018 was Nantahala Capital Management, an estimated $20.3M added.
- The largest Akebia Therapeutics seller in Q1 2018 was Farallon Capital Management, an estimated $12.3M sold.
Based on aggregated 13F filings for Q1 2018.